Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients

Jayashri Sankaranarayanan, Tom Reardon, Keith M. Olsen

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a PPI (39% enteral-only, 34% parenteral-only, 27% both-route) in a Midwest USA academic medical center. Possible cost-savings with sensitivity analysis were estimated as differences in drug costs (US dollars) between switch eligible parenteral and alternate enteral-PPI medication doses. In multivariate logistic-regression of switch criteria (any oral-medication, orogastric-tube, nothing by oral route), significant correlate for enteral versus parenteral PPI-use was any oral-medication use but not orogastric-tube. Using enteral esomeprazole/lansoprazole instead of parenteral (esomeprazole/pantoprazole) PPI (in 37% i.e. 696 of 1895 switch-eligible doses) would have saved US2384.17 or US3564.86, respectively. By switching eligible patients on oral-medications or on orogastric-tube from parenteral- to enteral-PPI, institutions can realize significant drug cost-savings.

Original languageEnglish (US)
Pages (from-to)741-749
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2014

Keywords

  • acid suppressive agent
  • correlates
  • drug cost saving
  • intensive care
  • intravenous to oral switch

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients'. Together they form a unique fingerprint.

  • Cite this